SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0000950170-24-043865
Filing Date
2024-04-12
Accepted
2024-04-12 08:00:15
Documents
13
Period of Report
2023-12-31

Document Format Files

Seq Description Document Type Size
1 10-K/A fusn-20231231.htm   iXBRL 10-K/A 836852
2 EX-31.3 fusn-ex31_3.htm EX-31.3 7787
3 EX-31.4 fusn-ex31_4.htm EX-31.4 7880
  Complete submission text file 0000950170-24-043865.txt   3204706

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT fusn-20231231.xsd EX-101.SCH 1545746
16 EXTRACTED XBRL INSTANCE DOCUMENT fusn-20231231_htm.xml XML 11068
Mailing Address 270 LONGWOOD ROAD SOUTH HAMILTON A6 L8P 0A6
Business Address 270 LONGWOOD ROAD SOUTH HAMILTON A6 L8P 0A6 289-799-0891
Fusion Pharmaceuticals Inc. (Filer) CIK: 0001805890 (see all company filings)

IRS No.: 000000000 | State of Incorp.: Z4 | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-39344 | Film No.: 24840018
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)